

# BMJ Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

George Krasopoulos, Stephanie J Brister, W Scott Beattie and Michael R Buchanan

BMJ published online 17 Jan 2008;  
doi:10.1136/bmj.39430.529549.BE

---

Updated information and services can be found at:  
<http://bmj.com/cgi/content/full/bmj.39430.529549.BE1>

---

*These include:*

**Data supplement**

"Web references"

<http://bmj.com/cgi/content/full/bmj.39430.529549.BE/DC1>

**References**

This article cites 28 articles, 9 of which can be accessed free at:  
<http://bmj.com/cgi/content/full/bmj.39430.529549.BE1#BIBL>

1 online articles that cite this article can be accessed at:  
<http://bmj.com/cgi/content/full/bmj.39430.529549.BE1#otherarticles>

**Rapid responses**

You can respond to this article at:  
<http://bmj.com/cgi/eletter-submit/bmj.39430.529549.BE1>

**Email alerting service**

Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

---

**Notes**

---

To order reprints follow the "Request Permissions" link in the navigation box

To subscribe to *BMJ* go to:  
<http://resources.bmj.com/bmj/subscribers>

## Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis

George Krasopoulos, cardiovascular surgery fellow,<sup>1</sup> Stephanie J Brister, associate professor,<sup>1</sup> W Scott Beattie, R Fraser Elliot chair in cardiac anaesthesia,<sup>2</sup> Michael R Buchanan, professor<sup>3</sup>

<sup>1</sup>University Health Network, Division of Cardiovascular Surgery, Toronto General Hospital

<sup>2</sup>University Health Network, Department of Anaesthesiology, Toronto General Hospital

<sup>3</sup>McMaster University, Department of Pathology and Molecular Medicine, Hamilton, ON, Canada L8S 4L8

Correspondence to: M R Buchanan [mbuchan@mcmaster.ca](mailto:mbuchan@mcmaster.ca)

doi:10.1136/bmj.39430.529549.BE

### ABSTRACT

**Objective** To determine if there is a relation between aspirin “resistance” and clinical outcomes in patients with cardiovascular disease.

**Design** Systematic review and meta-analysis.

**Data source** Electronic literature search without language restrictions of four databases and hand search of bibliographies for other relevant articles.

**Review methods** Inclusion criteria included a test for platelet responsiveness and clinical outcomes. Aspirin resistance was assessed, using a variety of platelet function assays.

**Results** 20 studies totalling 2930 patients with cardiovascular disease were identified. Most studies used aspirin regimens, ranging from 75-325 mg daily, and six studies included adjunct antiplatelet therapy.

Compliance was confirmed directly in 14 studies and by telephone or interviews in three. Information was insufficient to assess compliance in three studies. Overall, 810 patients (28%) were classified as aspirin resistant. A cardiovascular related event occurred in 41% of patients (odds ratio 3.85, 95% confidence interval 3.08 to 4.80), death in 5.7% (5.99, 2.28 to 15.72), and an acute coronary syndrome in 39.4% (4.06, 2.96 to 5.56). Aspirin resistant patients did not benefit from other antiplatelet treatment.

**Conclusion** Patients who are resistant to aspirin are at a greater risk of clinically important cardiovascular morbidity long term than patients who are sensitive to aspirin.

### INTRODUCTION

There is no debate that long term aspirin use attenuates the risks of myocardial infarction, stroke, and vascular related deaths in patients with cardiovascular disease,<sup>1</sup> but a significant number of patients prescribed aspirin as antithrombotic therapy have major adverse vascular related events each year.<sup>2</sup> Consequently other antiplatelet agents in addition to aspirin have been prescribed for certain patients.<sup>w16-w20</sup>

The major controversy about aspirin therapy is why particular patients do not benefit from such therapy and how they might be identified. It has been suggested that some patients require a higher dose of aspirin than is normally recommended to achieve the expected antiplatelet effect—for example, inhibition of platelet

function or inhibition of platelet thromboxane A<sub>2</sub> synthesis.<sup>3-6w10</sup> It is unclear whether these patients simply receive too low an aspirin dose, are not compliant, have differing abilities to absorb aspirin, or have an underlying genetic disposition that renders aspirin ineffective.<sup>27-11</sup> Such patients have been labelled aspirin “resistant”—that is, their platelets are not affected in the same way or are affected differently from the platelets of those who seem to benefit from aspirin therapy (aspirin “sensitive” patients with no subsequent adverse cardiovascular event).<sup>12-17w1 w4-w9 w11-w13</sup> Little consistency exists about which measure should be used to identify patients who seem resistant to aspirin.<sup>12-17w1 w4-w9 w11-w13</sup> Also, few studies have assessed the effect of aspirin resistance on clinically important outcomes.

We systematically reviewed studies of aspirin resistance and its effect on adverse cardiovascular outcomes. We hypothesised that aspirin resistance is real and is clinically relevant—that is, it significantly affects the risk of cardiovascular, cerebrovascular, and vascular related events.<sup>11w6</sup>

### METHODS

Using no language restrictions we systematically searched for studies on antiplatelet therapy from 1966 to the present through Medline, Embase, CHINAHL, and the Cochrane Controlled Trials Registry. We used the search terms “acetylsalicylic acid”, “aspirin”, “antiplatelet”, “antiplatelets”, “platelets”, “drug resistance”, “aspirin resistance”, and “platelet resistance”. The initial search identified 36 573 papers. When we refined our search to aspirin resistance the number of papers was reduced to 320, and 210 remained when we further refined the search to aspirin resistance and clinical outcome. An expert hand searched and reviewed citations within these 210 key papers. We reviewed 268 abstracts for evidence of data related to aspirin resistance and its relation to clinical outcome. We excluded papers that did not contain a direct measure of platelet function or any data on clinical outcome in relation to aspirin resistance. Overall we independently reviewed 57 papers in detail. Twenty papers met the inclusion criteria.<sup>w2 w3 w10-w13 w14-w20</sup> Figure 1 shows the flow of papers through the trial.




Fig 1 Flow of papers through review process

We each reviewed and tabulated the data from every paper. When possible we approached the original authors to verify our interpretation of their data. Data that had been confirmed for accuracy were then analysed using Review Manager 4.2.8 for meta-analysis.

#### Inclusion and exclusion criteria

We included studies that met the following criteria: (a) participants were receiving aspirin therapy as an antithrombotic; (b) participants were classified prospectively as aspirin sensitive or aspirin resistant before the ascertainment of any clinical outcome, or were grouped on the basis of clinical outcome and then classified for aspirin status (we considered patients to be aspirin sensitive if their platelets responded as expected to aspirin treatment, and platelet function, however measured, was inhibited, and we considered patients to be aspirin resistant if their agonist induced platelet response was not inhibited by aspirin as expected); (c) there was adequate allocation concealment such that investigators were blinded to the patients' aspirin sensitive and aspirin resistant status; (d) a measure of prospective clinical outcome was used in both groups of patients; and (e) patients receiving other antiplatelet treatment were also included. (The expectation was that there would be an attenuation of the rate of any adverse effects associated with aspirin resistance in the presence of a second platelet inhibitor, given the perceived rationale for prescribing the second antiplatelet agent. Alternatively, if no attenuation of any adverse events occurred in the presence of a second platelet inhibitor, this could possibly reflect a lack of any benefit of the second platelet inhibitor.)

The 37 studies that we excluded did not assess an agonist induced platelet response to ascertain patients' aspirin resistance status, or lacked an assessment of the relation between aspirin resistance and clinical morbidity or mortality. This included any study that measured only thromboxane A<sub>2</sub> (thromboxane B<sub>2</sub>) levels,<sup>8</sup> because inhibition of thromboxane B<sub>2</sub> synthesis could simply reflect a measure of patient compliance.

We considered several platelet function assays acceptable for inclusion: whole blood platelet function tests, such as the platelet function analyser 100 test (Dade Behring, Deerfield, IL, USA); light transmission platelet rich plasma platelet function tests; and bleeding time as a function of platelet haemostasis. The platelet function analyser 100 test is thought to measure shear stress induced platelet activation—that is, adherence to and occlusion of a membrane coated with a platelet agonist *in vitro*. Light transmission aggregometry measures the increase in light transmitted through a suspension of platelet rich plasma exposed to various agonists. The Surgicutt II (ITC Commercial Group, Edison, NJ, USA) is thought to measure platelet dependent haemostasis. None of these assays were weighted differently from one another from the perspective of one test being better than another in identifying aspirin resistance, particularly as no consensus on this has been reached.<sup>18</sup>

#### Outcome measures

The papers reported on four primary outcomes: any cardiovascular or cerebrovascular event (for example, fatal or non-fatal myocardial infarction, stroke, vascular related event); death; acute coronary syndromes (for example, non-ST segment elevation myocardial infarction, ST elevation myocardial infarction, unstable angina); and failure of vascular interventions (vein failure or reocclusion, revascularisation, and vascular restenosis).

#### Data collection and analysis

We collected personal and clinical outcome data from the included studies. Before analysis we confirmed the accuracy of the data. We rechecked any disparate data and corrected accordingly. When possible we contacted one of the original authors by email to verify the accuracy of their data and the interpretation of their results by the current investigators. Nurses fluent in Chinese or Czech translated the two foreign language studies.<sup>w4 w20</sup>

#### Statistical analysis

We present the results as odds ratios with 95% confidence intervals. We considered a two tailed P value of less than 0.05 as significant. Calculations were done using the fixed effects model. Heterogeneity was assessed using the Q test (a search being initiated by a heterogeneity >50%). Finally, we determined the robustness of our findings by removing the most positive studies one at a time. Planned sensitivity analyses were assessment of the platelet function assays, dose of aspirin, and the inclusion of another platelet inhibitor. We used a computer assisted S-plus/R function to fit meta-analytic mixed random and fixed effects models to do a metaregression analysis of any dose response.<sup>19</sup> Potential publication bias was assessed by a funnel plot, and we used an Egger's regression test to assess any dose related effect.<sup>20</sup> We used the checklist recommended by the meta-analysis of observational studies in epidemiology group.<sup>21</sup>

**Table 1 | Characteristics of included studies**

Study	Design; quality*	Patient population	No of patients	Aspirin (mg/d)	Adjunct antiplatelet therapy	Compliance	No of patients aspirin resistant; No of patients aspirin sensitive	Assay	Outcome measures
Borna et al 2005 <sup>w1</sup>	Cohort; A	Acute coronary syndrome	64	75-320	—	Verbal	20; 44	Platelet function analyser 100	Acute coronary syndrome
Cotter et al 2004 <sup>w2</sup>	Cohort; A	Post myocardial infarction	61	100	—	Baseline: aspirin in hospital	9; 52	Platelet aggregation†	Cardiovascular or cerebrovascular events‡
Grundmann et al 2003 <sup>w3</sup>	Cohort; A	Cardiovascular disease or stroke	53	100	—	?	12; 41	Platelet function analyser 100	New strokes
Stejskal et al <sup>w4</sup>	Cohort; A	Acute coronary syndrome	103	100	—	?	73; 30	Platelet aggregation†	Acute coronary syndrome
Andersen et al 2003 <sup>w5</sup>	Prospective randomised controlled; A	Post myocardial infarction	71	160	—	Repeat measures	25; 46	Platelet function analyser 100	Cardiovascular or cerebrovascular events‡
Buchanan et al 2000 <sup>w6</sup>	Multicentre prospective descriptive; A	Post coronary artery bypass grafting	289	325	—	Baseline: aspirin in hospital	158; 131	Serum thromboxane B <sub>2</sub> level, bleeding time§	Cardiovascular or cerebrovascular events‡
Gum et al 2003 <sup>w7</sup>	Cohort; A	Cardiovascular disease	326	325	—	Verbal	17; 309	Platelet aggregation†	Cardiovascular or cerebrovascular events‡
Hobikoglu et al 2005 <sup>w8</sup>	Cohort; A	Acute coronary syndrome	204	100-300	—	Baseline: aspirin in hospital	69; 135	Platelet function analyser 100	Cardiovascular or cerebrovascular events‡
McCabe et al 2005 <sup>w9</sup>	Multicentre cohort; A	Cerebrovascular	47	75-300	—	Verbal	22; 25	Platelet function analyser 100	Cardiovascular or cerebrovascular events‡
Meuller et al 1997 <sup>w10</sup>	Cohort; D	Peripheral vascular disease	96	100	—	Baseline: aspirin in hospital	41; 55	Whole blood aggregometry	Vascular occlusion or deterioration
Poston et al 2006 <sup>w11</sup>	Cohort; A	Post coronary artery bypass grafting	225	325	—	Baseline: aspirin in hospital	49; 176	TEG, whole blood aggregometry, thromboxane B <sub>2</sub>	Graft failure
Yilmaz et al 2005 <sup>w12</sup>	Prospective case-control; A	Post coronary artery bypass grafting	28	100-325	—	Baseline: aspirin in hospital	8; 20	Platelet function analyser 100	Graft failure
Grotemeyer et al <sup>w13</sup>	Cohort; A	Stroke	174	1500	—	Baseline: aspirin in hospital	60; 114	Platelet adhesion	Cardiovascular or cerebrovascular events‡
Parmukcu et al 2007 <sup>w14</sup>	Cohort; D	Coronary artery disease	234	100-300	—	?	52; 182	Platelet function analyser 100	Cardiovascular or cerebrovascular events‡
Berroschot et al 2006 <sup>w15</sup>	Cohort; A	Stroke	240	300	Aspirin plus clopidogrel for aspirin resistant patients	Baseline: aspirin in hospital	30; 210	Platelet aggregation†	New strokes
Chen et al 2005 <sup>w16</sup>	Cohort; A	Percutaneous coronary intervention	151	80-320	Aspirin plus clopidogrel	Baseline: aspirin in hospital	29; 122	Ultegra	Acute coronary syndrome
Chen et al 2004 <sup>w17</sup>	Cohort; A	Percutaneous coronary intervention	117	80-320	Aspirin plus clopidogrel	Baseline: aspirin in hospital	22; 95	VerifyNow	Acute coronary syndrome
Faraday et al 2004 <sup>w18</sup>	Cohort; A	Acute coronary syndrome	30	325	Aspirin plus clopidogrel and tirofiban	Baseline: aspirin in hospital	2; 28	Platelet aggregation†	Acute coronary syndrome
Gurbel et al 2003 <sup>w19</sup>	Cohort; A	Percutaneous coronary intervention	191	81-325	Aspirin plus clopidogrel and glycoprotein IIb/IIIa	Baseline: aspirin in hospital	45; 146	TEG	Cardiovascular or cerebrovascular events‡
Zhang et al 2005 <sup>w20</sup>	Cohort; D	Percutaneous coronary intervention	256	100	Plus clopidogrel	Baseline: aspirin in hospital	67; 189	Platelet aggregation†	Acute coronary syndrome

\*Risk of bias: from A (low) to D (insufficient information for assessment of bias).

†Laboratory specific platelet aggregation assays, using stimuli such as arachidonic acid, adenosine diphosphate, or collagen.

‡Fatal or non-fatal events.

§Bleeding time using Surgicutt II.




Fig 2 Risk of any cardiovascular event in aspirin resistant patients

**RESULTS**

The systematic search identified 20 studies, totalling 2930 patients with cardiovascular disease (17 cohort studies; one multicentre, descriptive study; and two case-control studies). The studies included only prospectively collected data on a variety of vascular related diseases: previous stroke (414 patients), acute coronary syndrome (n=401), myocardial infarction (n=132), coronary arterial bypass grafting (n=542), percutaneous coronary intervention (n=715), stable cardiovascular disease (n=760), and peripheral vascular disease (n=96; table 1). All but three of the studies were assessed as of A quality (low risk of bias). In the three studies incomplete reporting prevented the ascertainment of risk of underlying bias.<sup>w10 w14 w20</sup> These studies were small, however, and their inclusion or exclusion was unlikely to significantly affect overall reporting. No studies were of a prospective, randomised clinical design (with or without placebo controls).

Thirteen studies reported on aspirin only as antiplatelet therapy, with daily doses ranging from 75-325 mg; one study used a daily dose of 500 mg three times daily, and six studies included a loading dose of clopidogrel (Plavix) or another antiplatelet inhibitor tirofiban hydrochloride, or both, as adjunct therapy.<sup>w15-w20</sup> Compliance was assessed by the primary study investigator in 17 of the 20 studies.

A variety of assays were used to assess patients' aspirin status. These included measuring serum thromboxane A<sub>2</sub> in relation to platelet haemostasis,<sup>w6</sup> a platelet or collagen adhesion assay,<sup>w13</sup> platelet rich plasma aggregometry,<sup>w2 w4 w7 w15 w18 w20</sup> whole blood platelet aggregometry, such as the platelet function analyser 100 test,<sup>w1 w3 w5 w8 w9 w12 w14</sup> or some combination or modification thereof.<sup>w10 w13 w16 w17 w19</sup> Table 1 summarises the characteristics of the included studies.

Overall, 2120 of the 2930 patients were classified as aspirin sensitive and the remaining 810 (28%) as aspirin resistant. Aspirin resistance was less prevalent in men than in women and higher in patients with previous renal impairment ( $P<0.001$  and  $P<0.03$ ). No other differences in the clinical and personal characteristics between aspirin resistant and aspirin sensitive patients were apparent (table 2).

All aspirin resistant patients, regardless of underlying clinical symptoms, were at a greater risk of death, acute coronary syndrome, failure in vascular intervention, or a new cerebrovascular event (table 3): 39% of aspirin resistant patients compared with 16% of aspirin sensitive patients had a cardiovascular event (odds ratio 3.85, 95% confidence interval 3.08 to 4.80;  $P<0.001$ , fig 2). The odds ratios for increased acute coronary syndrome, graft failure, or a new cerebrovascular event were 4.06, 4.35, and 3.78. Moreover, the odds ratio for increased mortality in aspirin resistant patients was 5.99 (2.28 to 15.72;  $P<0.003$ ).

In the results for cardiovascular outcome the overall heterogeneity was 68.3%. Most of the heterogeneity (50.3%) was contributed to by the eight studies that used the whole blood platelet function analyser 100 test; 33% of those patients were identified as aspirin resistant (2.94, 1.88 to 4.55;  $P=0.00001$ ). In contrast, heterogeneity was 0% in the seven studies that used a platelet rich plasma aggregation assay; only 16% of patients were identified as aspirin resistant, and these patients had a higher odds ratio (3.85, 2.5 to 5.88;  $P<0.001$ ).

Data were insufficient to assess the effect of the whole blood aggregometry assays TEG (Haemoscope, Niles, IL, USA) and VerifyNow (Accumetrics, San Diego, CA, USA) and bleeding time assays on overall heterogeneity.

In the planned sensitivity analysis no evidence was found of a dose-response relation between aspirin resistance and any cardiovascular outcome in those patients who received aspirin alone or who received a second antiplatelet treatment (table 3, fig 3). Thus the overall odds ratio was 3.28 (95% confidence interval 2.39 to 4.49,  $P<0.001$ ), but no relation was found between dose and adverse outcome measures ( $R^2=0.0046$ ; fig 4). Moreover, concomitant therapy with clopidogrel or tirofiban (an inhibitor of platelet glycoprotein IIb/IIIa), or both, provided no benefit to those patients identified as aspirin resistant (aspirin and clopidogrel, 3.06, 1.99 to 4.70; aspirin alone, 2.52, 1.79 to 3.56; fig 3).

A funnel plot indicated an absence of published data of small studies and negative results—that is, no studies reported no adverse effect in aspirin resistant patients (lower left quadrant in figure 5). Little evidence was, however, found of publication bias using the classic

funnel plot (fig 5) or a Macaskill<sup>22</sup> modification (not shown).

## DISCUSSION

Meta-analysis showed that patients who are “resistant” to aspirin are at greater risk of clinically important adverse cardiovascular events, regardless of the assay used to measure aspirin resistance. Not only did aspirin resistance have an effect on clinical outcome but this risk was not ameliorated by currently used adjunct antiplatelet therapies.

Patients who were classified as aspirin resistant were at about a fourfold increased risk of non-fatal and fatal cardiovascular, cerebrovascular, or vascular events while taking aspirin than their aspirin sensitive counterparts. This risk can be generalised to a wide variety of patient populations with cardiovascular or cerebrovascular disease.


### Putting our study into context

The concept of aspirin resistance has been debated since the 1980s,<sup>24 9-11w1321</sup> but discussions in the recent literature have focused on reasons why aspirin resistance is probably a misnomer, and to which little clinical relevance can be attached.<sup>211</sup> More recently, however, interest has been renewed in aspirin resistance, which has focused primarily on identifying the platelet related assay that best reflects the phenomenon.<sup>211 18 23-26</sup> To date this issue has not been resolved. Few studies have tackled the matter of aspirin resistance and its impact on clinical outcome. Given the lack of resolution of a suitable assay and the limited size, number, and applicability of individual studies, we carried out a systematic review and meta-analysis of all available studies from 1960 to the present to understand better the relation between aspirin resistance and

**Table 2 | Characteristics of included patients**

Characteristic	Aspirin resistant patients	Aspirin sensitive patients	Heterogeneity (%)	Odds ratio (95% CI)	P value	No of studies (n=20)	No of patients (n=2930)
Mean (SD) age (years)	62.2 (10.1)	62.7 (11.3)	0	0.51 (−0.82 to 1.84)	0.45	7	1554
No (%) of men	(71.4)	(79.5)	—	2.08 (1.54 to 2.82)	0.001	7	1554
Hypertension	202/397	507/854	0	1.07 (0.80 to 1.44)	0.65	6	1251
Diabetes	106/414	334/4460	64.5	0.91 (0.68 to 1.21)	0.51	7	1554
Dyslipidaemia	158/278	292/483	0	0.98 (0.71 to 1.36)	0.91	4	761
Smoking	178/444	337/1190	48.3	0.75 (0.54 to 1.04)	0.08	7	1634
Clinical history:							
Acute coronary syndrome	48/206	260/878	48.5	1.08 (0.73 to 1.60)	0.7	7	1084
Stable angina	145/212	412/587	47.9	0.95 (0.66 to 1.37)	0.78	5	799
Surgery	173/183	262/460	NE	1.25 (0.46 to 3.37)	0.86	3	643
Percutaneous coronary intervention	4/17	105/309	NE	0.6 (0.19 to 1.88)	0.38	1	326
Renal impairment	11/51	22/217	0	2.44 (1.09 to 5.44)	0.03	2	268
Cerebrovascular event	113/129	365/659	NE	1.23 (0.15 to 9.86)	0.85	4	788

NE=not estimable.



**Fig 3** Risks of any cardiovascular event in aspirin resistant and aspirin sensitive patients treated with aspirin alone, and aspirin and clopidogrel (with or without an inhibitor of platelet glycoprotein IIb/IIIa)

clinical outcome, regardless of the assay used to identify patients as aspirin resistant.

We thought that the pooling of data from studies using a variety of assays for aspirin resistance was both a limitation and a strength of our study. Specifically, we rationalised that if any or all of the assays were unreliable or inaccurate in identifying patients with aspirin resistance, then any real aspirin resistant effect on clinical outcome would be undetectable. If, however, most or all of the assays did reflect some rationale and some degree of validity and sensitivity, albeit variable, then any real impact of aspirin resistance on clinical outcome should be apparent. This interpretation seemed more logical to us, since we would expect that most, if not all, investigators had considered their particular assay in good faith and with a scientific basis.

The findings of a recent review and meta-analysis of laboratory testing for aspirin resistance and clinical outcome<sup>27</sup> are consistent with those of our study. These investigators reported on 15 studies, 10 of which overlapped with our findings, and another three that were related to pilot or follow-up studies cited by us. Despite any discrepancy in the number of papers, the recent view also concluded that aspirin resistant patients “exhibit significantly higher risks of recurrent cardiovascular events compared with patients identified as (laboratory) aspirin sensitive.”<sup>27</sup>

Platelet inhibitors such as clopidogrel and tirofiban did not provide any benefit to aspirin resistant patients. The relative effectiveness of these newer antiplatelet agents compared with aspirin has been established when their effectiveness was compared with that of aspirin alone in aspirin treated patients. For example,

the Aspirin Trialists' Collaboration<sup>1</sup> suggested that when used as an antiplatelet agent aspirin provides an overall 25% risk reduction. These investigators did not, however, consider aspirin resistance and how it might influence overall risk reduction. When the data reported by the Aspirin Trialists' Collaboration are reassessed with an aspirin resistance odds ratio factored in, the risk reduction in aspirin sensitive patients is likely to be greater than a 50% risk reduction, whereas in aspirin resistant patients the risk seems to be noticeably increased.<sup>7</sup> Thus the relative benefit of alternate antiplatelet agents needs to be reassessed prospectively against a group of aspirin sensitive patients. It is possible that the modest reported 10% better effect of alternate platelet therapies compared with aspirin alone (the overall 25% risk reduction) may well be 20% less effective when compared with the potentially greater than 50% beneficial effect of aspirin in aspirin sensitive patients. If so the current strategies for antiplatelet therapy may need to be rethought.

Our analyses also indicate that the effect of aspirin resistance on clinical outcome is applicable to the entire community of aspirin treated patients at risk of cardiovascular and cerebrovascular events. Thus the increased risk of these events in aspirin resistant patients occurs in those with stable cardiovascular disease or coronary artery disease, those who have had percutaneous coronary intervention or coronary artery bypass grafting, those undergoing other vascular procedures, and after stroke.

We found that aspirin resistant patients are at a greater risk of clinically important adverse cardiovascular events, indicating that such resistance is a biological entity that should be considered when recommending aspirin as antiplatelet therapy.

#### Limitations of study

We assessed 17 of the 20 included studies as of A quality—that is, they had a low risk of bias.<sup>w1-w9 w11-w13 w15 w17-w20</sup> These studies had an acceptable allocation of blindness, including an assessment of compliance, and a blinded strategy for measuring aspirin resistance

status and clinical outcome. In three studies<sup>w10 w14 w20</sup> data on compliance with blindness were insufficient or they lacked sufficient information to assess quality objectively, and these studies were ranked D. As these studies met the rest of the inclusion criteria and contained 586 patients (20% of the total), we included them in our analysis. We can not, however, exclude the possibility that these studies may have skewed our analysis. As the overall outcomes of these studies were consistent with the overall analysis of the other 17 studies, however, we do not think this was the case.

We were unable to provide any evidence related to comorbidity and its effects on aspirin resistance. None of the included studies provided any specific information about the comorbidity characteristics between those patients who had an adverse event and those who did not in either aspirin status group. Thus the risk from being aspirin resistant seemed to be lower in men and higher in patients with a history of renal impairment. We can not provide an explanation for either at this time. The sex related difference occurred in about half of the 2930 patients, and this difference may be real. We have previously reported on sex related differences in aspirin pharmacodynamics and pharmacokinetics.<sup>28</sup>

The relation between being resistant to aspirin and having a history of renal impairment is possibly an anomaly. This relation was seen in only two studies,<sup>w16 w17</sup> both from the same centre, concerning an Asian population, and representing less than 9% of the patients analysed. Thus the apparent relation between a history of renal impairment and aspirin status can not be generalised to the entire patient population. Whether this relation is unique to the Asian population is not clear but merits further exploration. We recommend therefore that future studies should consider these relations, including sex, comorbidities, and ethnicity, as these characteristics may well affect the relative risks of adverse effects in a patient population that is already at high risk.

We were unable to determine which platelet function test best identifies aspirin resistant patients. It might be argued that the platelet aggregation assays (using

**Table 3 | Risks of adverse outcomes and aspirin dose response in patients who are resistant to aspirin**

Variable	No of studies (n=20)	No of patients (n=2930)	Odds ratio (95% CI)	Heterogeneity (%)	P value
Outcome:					
All cerebrovascular events*	20	2930	3.85 (3.08 to 4.80)	68.3	<0.001
Death	4	728	5.99 (2.28 to 15.72)	5.5	<0.003
Acute coronary syndrome	9	1275	4.06 (2.96 to 5.56)	58.6	<0.001
Graft failure	3	420	4.35 (2.26 to 8.37)	28.2	<0.001
New cerebral event	4	340	3.78 (1.25 to 11.41)	38.1	<0.02
Dose response:					
75-100 mg/day	3	228	21.17 (8.83 to 50.77)	74.7	<0.003
>100-325 mg/day	9	1,309	2.81 (2.00 to 3.94)	37.9	<0.001
500 mg three times daily	1	174	14.53 (NA)	NA	<0.001
All doses	12	1710	3.28 (2.39 to 4.49)	56.7	<0.001

NA=not applicable.

\*Fatal or non-fatal cardiovascular or cerebrovascular events (death, stroke, myocardial infarction), acute coronary syndrome, acute coronary syndrome.




Fig 4 Dose related effect of aspirin on cardiovascular outcome

platelet rich plasma) are the better assays since those tests label fewer patients as aspirin resistant with less heterogeneity and a higher odds ratio than the whole blood platelet function assays, such as the platelet function analyser 100 assay. Moreover, lower heterogeneity was found with the platelet aggregation assays despite the use of a variety of agonists. It also can be argued that the greater heterogeneity seen when using the whole blood platelet function assays better reflects what is happening *in vivo*, as this type of assay concerns other cell types, such as inflammatory cells, that could contribute to the overall response of circulating platelets in aspirin resistant patients. The responses to particular agonists in aspirin resistant patients has yet to be elucidated. This is complicated further by the current limited understanding of the underlying mechanism of platelet function related to aspirin resistance. We previously suggested that aspirin resistance is independent of the platelet cyclo-oxygenase pathway and thromboxane B<sub>2</sub> (thromboxane A<sub>2</sub>) inhibition and more related to an effect of aspirin (its salicylate moiety) on lipoxygenase dependent 12 HETE synthesis, integrin expression, and platelet adhesion in itself.<sup>4,6</sup> More recent studies suggest that a pathway independent of cyclo-oxygenase-1 and cyclo-oxygenase-2 affects aspirin resistance.<sup>24,25</sup> It is worth noting that a systematic review found a higher prevalence of aspirin resistance when using the platelet function analyser 100 assay than when using a platelet rich plasma aggregation assay, similar to our findings.<sup>18</sup> These investigators also adjusted the prevalence of aspirin resistance on the basis of dose, study population, and aspirin resistance assay used. We did not do this, however, because we did not find any dose related effect (as with the Aspirin Trialists' Collaboration<sup>1</sup>) and could not exclude other variables such as comorbidity, which the previous systematic review also did not exclude.<sup>18</sup> Therefore we suggest that this matter can only be resolved by a prospective study using a battery of aspirin resistance assays, each of which must be related to clinical outcome measures to ascertain specificity, sensitivity, and relevance. Only then can the best assay be identified.

Data were insufficient in the included studies to establish whether patients initially identified as aspirin

resistant remained aspirin resistant or whether patients identified as aspirin sensitive subsequently became aspirin resistant. Either possibility could skew the overall prevalence of being aspirin resistant. Some investigators have suggested that chronic aspirin use is ineffective after about two years.<sup>14,29</sup> This possible variance is unlikely to alter the overall increased odds ratio of having an adverse event when aspirin resistant, because the clinical outcome measures in these studies were related to the initial assay for aspirin resistance.

Only a few of the studies measured a biochemical marker of compliance (for example, thromboxane A<sub>2</sub> or thromboxane B<sub>2</sub>). However, most of the other investigators identified their patients as aspirin resistant or aspirin sensitive in hospital—that is, in a controlled environment after a specific procedure and before and after known aspirin treatment. Thus aspirin status measured at that time could be assured independent of non-compliance. As such it is difficult to imagine that most patients had subsequently become non-compliant, and yet a significant difference in odds ratios would remain between the initially labelled aspirin resistant patients and those who were sensitive to aspirin.

Finally, a classic funnel plot suggested a modest publication bias, since there was an absence of small patient number studies that reported on a negative or no relation between aspirin resistance and adverse clinical outcomes. We found little evidence of any publication bias using a classic funnel plot and Egger's and Macaskill modification,<sup>22</sup> suggesting that the overall findings of our study were not skewed by publication bias.

#### Recommendation and future directions

Although this study shows that aspirin resistance adversely affects clinical outcomes whenever aspirin is used alone or in combination with another antiplatelet agent, several issues need resolution or clarification:

Firstly, we strongly advise that doctors continue their current practice in prescribing aspirin for chronic therapy to prevent adverse cardiovascular events as the overall risk reduction is well reported.<sup>1</sup> We also recommend that patients are fully informed about the possible adverse effects of aspirin as it is possible that




Fig 5 Funnel plot for detection of possible publication bias

**WHAT IS ALREADY KNOWN ON THIS TOPIC**

Many patients with cardiovascular disease are “resistant” or non-responsive to aspirin

**WHAT THIS STUDY ADDS**

Aspirin resistance can be measured by a variety of tests, all of which are associated with clinically important adverse events

the currently perceived overall benefit in all aspirin treated patients (about a 25% decrease in risk) is more likely offset by the fourfold increased risk in the 16% to 30% subpopulation of patients identified as aspirin resistant.

Studies need to be designed to determine the most useful test to identify aspirin resistance and identify alternative effective therapies for patients who are resistant to aspirin. Finally, we suggest that the term aspirin resistant is a misnomer. Aspirin non-responsiveness may be a more appropriate label until a better understanding is reached about what particular platelet function is involved.

We thank M Dang and M Kirchoff-Dobias for translating the Chinese and Czech papers. This study was supported by discretionary funds of SJB and MRB. The following authors verified our data interpretations: K Andersen (Norway); J Berrouschot, K-H Grotemeyer, and H Topka (Germany); W-H Chen (China); G Hobikoölu and MB Yilmaz (Turkey); and R Poston (United States).

**Contributors:** All authors did the literature search; reviewed the abstracts, papers, and data; and reviewed the manuscript and made appropriate amendments. MRB wrote the paper. All authors are guarantors for the paper.

**Funding:** None.

**Competing interests:** None declared.

**Ethical approval:** Not required.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

- Aspirin Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;308:81-106.
- Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. *N Engl J Med* 2005;353:2373-83.
- Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. *Am J Med* 2005;118:723-7.
- Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. *Can J Cardiol* 1995;11:221-7.
- Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. *J Am Coll Cardiol* 2004;43:972-8.
- Taylor DW, Barnett HJ, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose aspirin acetylsalicylic acid for patients undergoing carotid endarterectomy; a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. *Lancet* 1999;353:2179-84.

- Buchanan MR. Biological basis and clinical implications of acetylsalicylic acid resistance. *Can J Cardiol* 2006;22:149-51.
- Eikelboom JW, Hirsh J, Weitz JJ, Johnson M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. *Circulation* 2002;105:1650-5.
- Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. *J Thromb Haemost* 2003;1:1710-3.
- Hennekens CH, Schor K, Weisman S, Fitzgerald GA. Semantic complexity and aspirin resistance. *Circulation* 2004;110:1706-8.
- Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. *Atheroscler Thromb Vasc Biol* 2004;24:1980-7.
- Kuliczkowski W, Halawa B, Korolko B, Mazurek W. Aspirin resistance in ischemic heart disease. *Kardiol Pol* 2005;62:14-9.
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabaté M, Jimenez-Quevedo P, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. *Am J Cardiol* 2006;97:38-43.
- Hegason CM, Bolin KM, Hoff JA, Winkler SR, Manget A, Tortorice KL, et al. Development of aspirin resistance in persons with previous ischemic stroke. *Stroke* 1994;25:2331-6.
- Kawasaki T, Ozeki Y, Igawa T, Kambayashi J-I. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. *Stroke* 2000;31:591-6.
- Macchi L, Christianes L, Brabant S, Sorel N, Allal J, Mauco, et al. Resistance to aspirin is associated with platelet sensitivity to adenosine diphosphate. *Thromb Res* 2002;107:45-9.
- Zimmerman N, Wenk A, Kim U, Kienle P, Weber AA, Gams E, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. *Circulation* 2003;108:542-7.
- Hovens MMC, Snoep JD, Eikenboom JCJ, van der Bom JG, Mertens BJA, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. *Am Heart J* 2007;153:175-81.
- Veichtbauer: MiMa: An S-plus/R function to fit meta-analytic mixed-random and fixed effects models [computer and software]. [www.wvbauer.com](http://www.wvbauer.com).
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson CD, Rennie D, et al. Meta-analysis of observational studies in epidemiology. A proposal for reporting. *JAMA* 2000;283:2008-12.
- Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. *Stat Med* 2001;20:641-54.
- Van Ryn McKenna J, Buchanan MR. Relative effects of fluprofen on platelet 12-hydroxyeicosatetraenoic acid and thromboxane A<sub>2</sub> production: influence on collagen-induced platelet aggregation and adhesion. *Prost Leuko Med* 1989;36:171-4.
- Abaci A, Caliskan M, Bayram F, Yilmaz Y, Cetin M, Unal A, et al. A new definition of aspirin non-responsiveness by Platelet Function Analyser-100™ and its predictors. *Platelets* 2006;17:7-13.
- Heindl B, Becker BF. Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates post ischemic cardiac dysfunction, independent of COX function. *Nauyn-Schmiedeberg's Arch Pharmacol* 2001;363:233-40.
- Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Bamard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. *Circulation* 2006;113:2888-96.
- Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. *Arch Intern Med* 2007;167:1593-9.
- Buchanan MR, Rischke JA, Butt R, Turpie AGG, Hirsh J, Rosenfeld J. The sex-related differences in platelet function and aspirin pharmacokinetics in rabbits and man. *Thromb Res* 1983;29:469-70.
- Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schlier JJ, McClelland TJ, et al. ASA response and failure in cerebral infarction. *Stroke* 1993;25:345-50.

**Accepted:** 6 November 2007